Literature DB >> 2403483

c-erbB-2 oncoprotein expression in primary human tumors.

A McCann1, P A Dervan, P A Johnston, W J Gullick, D N Carney.   

Abstract

Using a specific antiserum (21N) to the c-erbB-2 oncoprotein, a total of 405 primary malignant human tumors arising in the breast (n = 191), lung (n = 110), colon/rectum (n = 23), bladder (n = 48), prostate (n = 23), and skin (n = 10) were stained immunohistochemically to detect those tumors that over-expressed this putative transmembrane receptor. Malignant cells showed intense positivity for this oncoprotein in 17% of the breast carcinomas, 4% of the colorectal tumors, 2% of the bladder tumors, and 1% of the nonsmall cell lung carcinomas. No positive staining was evident in the prostate, skin, or small cell lung carcinomas. This study shows that over-expression of the c-erbB-2 oncoprotein is common in breast cancer but relatively rare in the other malignancies studied. In addition, this oncoprotein can be identified readily in routine paraffin-embedded tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403483     DOI: 10.1002/1097-0142(19900101)65:1<88::aid-cncr2820650119>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

Authors:  Shang-Ru Wu; Tai-Shan Cheng; Wen-Chi Chen; Hsin-Yi Shyu; Chun-Jung Ko; Hsiang-Po Huang; Chen-Hsin Teng; Chia-Hau Lin; Michael D Johnson; Chen-Yong Lin; Ming-Shyue Lee
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  Lack of c-erbB-2 oncoprotein expression in male breast carcinoma.

Authors:  S B Fox; C A Day; S Rogers
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

3.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

4.  Analysis of c-erbB2 protein content of human glioma cells and tumor tissue.

Authors:  H H Engelhard; M Wolters; P S Criswell
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 5.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.

Authors:  P Shrestha; K Yamada; T Wada; S Maeda; M Watatani; M Yasutomi; H Takagi; M Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

Authors:  A H Arnaout; P M Dawson; S Soomro; P Taylor; N A Theodorou; M Feldmann; B M Fendly; H M Shepard; S Shousha
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

8.  Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.

Authors:  D W Ye; J F Zheng; S X Qian; Y J Ma
Journal:  Urol Res       Date:  1993-01

9.  Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.

Authors:  Surendra B Kolla; Amlesh Seth; Manoj K Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Rajeev Kumar
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

10.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.